Non-Steroidal Anti-inflammatory Drugs Decrease E2F1 Expression and Inhibit Cell Growth in Ovarian Cancer Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Valle, Blanca L ^a   D'Souza, Theresa ^a   Becker, Kevin G ^a   Wood III, William H ^a   Zhang, Yongqing ^a   Wersto, Robert P ^a   Morin, Patrice J ^a,b,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c American Association for Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; INDOMETACIN; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVARY CANCER; TUMOR XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DICLOFENAC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; E2F1 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOMETHACIN; MICE; MICE, NUDE; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876547241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061836     Document Type: Article

References (40)

1. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, et al. (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10: 501-507.
2. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, et al. (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379: 1602-1612.
3. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM, (2008) Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 98: 1781-1783.
4. Santander S, Cebrian C, Esquivias P, Conde B, Esteva F, et al. (2012) Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice. Int J Oncol 40: 527-534.
5. Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, et al. (2002) Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8: 202-209.
6. Fischer SM, Hawk ET, Lubet RA, (2011) Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) 4: 1728-1735.
7. Kudo T, Narisawa T, Abo S, (1980) Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann 71: 260-264.
8. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, et al. (1981) Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 41: 1954-1957.
9. Nagasawa H, Naito T, (1986) Inhibition by indomethacin of spontaneous mammary tumorigenesis in SHN mice. Breast Cancer Res Treat 8: 249-255.
10. Mayorek N, Naftali-Shani N, Grunewald M, (2010) Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity. PLoS One 5: e12715.
11. Moody TW, Switzer C, Santana-Flores W, Ridnour LA, Berna M, et al. (2010) Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. Lung Cancer 68: 154-160.
12. Zerbini LF, Tamura RE, Correa RG, Czibere A, Cordeiro J, et al. (2011) Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-kappaB inhibitors in ovarian cancer therapy. PLoS One 6: e24285.
13. Stratton JA, Rettenmaier MA, DiSaia PJ, (1983) In vivo antineoplastic activity of various biological response modifiers for tumors of the ovary and breast. J Clin Lab Immunol 11: 181-187.
14. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, et al. (2010) Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst 102: 812-827.
15. Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ Jr, et al. (1990) Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 45: 416-422.
16. Liu S, Brown CW, Berlin KD, Dhar A, Guruswamy S, et al. (2004) Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem 47: 999-1007.
17. Price JE, (2001) Xenograft models in immunodeficient animals: I. Nude mice: spontaneous and experimental metastasis models. Methods Mol Med 58: 205-213.
18. Crokart N, Radermacher K, Jordan BF, Baudelet C, Cron GO, et al. (2005) Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Res 65: 7911-7916.
19. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
20. Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, et al. (2007) Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. Mol Carcinog 46: 857-864.
21. Detjen KM, Welzel M, Wiedenmann B, Rosewicz S, (2003) Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int J Cancer 107: 844-853.
22. Brooks G, Yu XM, Wang Y, Crabbe MJ, Shattock MJ, et al. (2003) Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit vascular smooth muscle cell proliferation via differential effects on the cell cycle. J Pharm Pharmacol 55: 519-526.
23. Gao J, Niwa K, Sun W, Takemura M, Lian Z, et al. (2004) Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci 95: 901-907.
24. Singh R, Cadeddu RP, Frobel J, Wilk CM, Bruns I, et al. (2011) The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway. Apoptosis 16: 889-901.
25. Bayer BM, Kruth HS, Vaughan M, Beaven MA, (1979) Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin. J Pharmacol Exp Ther 210: 106-111.
26. Chirasani SR, Leukel P, Gottfried E, Hochrein J, Stadler K, et al. (2013) Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model. Int J Cancer 132: 843-53.
27. Chien J, Fan JB, Bell DA, April C, Klotzle B, et al. (2009) Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol 114: 3-11.
28. Zacharatos P, Kotsinas A, Evangelou K, Karakaidos P, Vassiliou LV, et al. (2004) Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. J Pathol 203: 744-753.
29. Ebihara Y, Miyamoto M, Shichinohe T, Kawarada Y, Cho Y, et al. (2004) Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression. Dis Esophagus 17: 150-154.
30. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, et al. (2002) Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 198: 142-156.
31. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, et al. (2007) Clinical relevance of E2F family members in ovarian cancer - an evaluation in a training set of 77 patients. Clin Cancer Res 13: 144-151.
32. Suh DS, Yoon MS, Choi KU, Kim JY, (2008) Significance of E2F-1 overexpression in epithelial ovarian cancer. Int J Gynecol Cancer 18: 492-498.
33. Yan KH, Yao CJ, Chang HY, Lai GM, Cheng AL, et al. (2010) The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol Carcinog 49: 235-246.
34. Cui W, Yu CH, Hu KQ, (2005) In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 11: 8213-8221.
35. Lau LM, Wolter JK, Lau JT, Cheng LS, Smith KM, et al. (2009) Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 28: 2024-2033.
36. Adhami VM, Afaq F, Ahmad N, (2001) Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem Biophys Res Commun 288: 579-585.
37. Du Y, Zhang S, Wang Z, Zhou W, Luan M, et al. (2008) Induction of apoptosis and cell cycle arrest by NS398 in oral squamous cell carcinoma cells via downregulation of E2 promoter-binding factor-1. Oncol Rep 20: 605-611.
38. Youns M, Efferth T, Hoheisel JD, (2011) Transcript profiling identifies novel key players mediating the growth inhibitory effect of NS-398 on human pancreatic cancer cells. Eur J Pharmacol 650: 170-177.
39. Lau KM, Chan QK, Pang JC, Li KK, Yeung WW, et al. (2010) Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion. Oncogene 29: 5475-5489.
40. Kwon HJ, Hong YK, Park C, Choi YH, Yun HJ, et al. (2010) Widdrol induces cell cycle arrest, associated with MCM down-regulation, in human colon adenocarcinoma cells. Cancer Lett 290: 96-103.